Efficacy and Safety of Bolus Injection of a Novel Thrombolytic Agent (SMRX-11) in Patients with Acute ST-segment Elevation Myocardial Infarction (STEMI): A Phase II Open-Label, Dose-Escalation, Multicentre, Angiographic Trial
Latest Information Update: 21 Jan 2020
At a glance
- Drugs SMRX 11 (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symmetrix Biotech
Most Recent Events
- 16 Jul 2018 Status changed from not yet recruiting to recruiting.
- 19 Mar 2014 New trial record